CD24、Smac在胃癌转移卵巢癌和原发性卵巢癌中的表达及其临床意义  

Expression and clinical significance of CD24 and Smac in ovarian metastases from gastric cancer and primary ovarian cancer

作　　者：徐春田 李瑞玲 Xu Chuntian;Li Ruiling(Department of Gynaecology,Norinco General Hospital,Xi’an 710065,China)

机构地区：[1]兵器工业总医院妇科,西安710065

出　　处：《中国实用医刊》2024年第24期4-8,共5页Chinese Journal of Practical Medicine

摘　　要：目的探讨细胞粘附分子24(CD24)、第二线粒体源性半胱氨酸酶激活因子(Smac)在胃癌转移卵巢癌和原发性卵巢癌中的表达及其临床意义。方法回顾性收集2021年3月至2024年3月于兵器工业总医院行手术治疗的79例卵巢原发性上皮肿瘤的蜡块(其中良性肿瘤15例, 交界性肿瘤18例, 恶性肿瘤46例)、12例胃癌转移卵巢癌蜡块。比较CD24和Smac在原发性卵巢肿瘤组织与胃癌转移卵巢癌组织中的阳性表达率及与临床病理参数的关系, 通过Spearman分析CD24、Smac在卵巢癌组织内表达的相关性。结果 CD24在恶性肿瘤中阳性表达率(84.78%, 39/46)高于交界性肿瘤(55.56%, 10/18)及良性肿瘤(13.33%, 2/15), P<0.05。Smac在良性肿瘤中阳性表达率(86.67%, 13/15)高于交界性肿瘤(66.67%, 12/18)及恶性肿瘤(60.87%, 28/46), P<0.05。原发性卵巢癌患者中CD24在有大网膜转移者中的阳性表达率高于无大网膜转移者(χ^(2)=7.14, P<0.05), 在Ⅲ~Ⅳ期组织中阳性表达率高于Ⅰ~Ⅱ期组织中(χ^(2)=6.26, P<0.05), 在有淋巴结转移者中的阳性表达率高于无淋巴结转移者(χ^(2)=4.57, P<0.05)。原发性卵巢癌患者Smac在有淋巴结转移者中的阳性表达率低于无淋巴结转移者(χ^(2)=4.76, P<0.05), 在Ⅰ~Ⅱ期组织中的阳性表达率高于Ⅲ~Ⅳ期组织(χ^(2)=4.00, P<0.05);Smac在原发性卵巢癌不同组织学分级(G1、G2、G3)中阳性表达率呈递减趋势(χ^(2)=19.14, P<0.05);Smac在浆液性囊腺癌的阳性表达率高于黏液性囊腺癌(χ^(2)=5.40, P<0.05)。原发性卵巢癌和胃癌转移卵巢组织中的CD24及Smac表达率比较差异未见统计学意义(P>0.05)。CD24、Smac在卵巢癌组织中的表达呈负相关(r=-0.38, P<0.05)。结论 CD24、Smac的表达与卵巢癌及其恶性程度密切相关。Objective To investigate the expression and clinical significance of cluster of differentiation 24(CD24)and second mitochondria-derived activator of caspases(Smac)in ovarian metastases from gastric cancer and primary ovarian cancer.MethodsRetrospective collection of paraffin blocks(tissue specimens)from 79 cases of primary ovarian epithelial tumors(including 15 cases of benign tumors,18 cases of borderline tumors and 46 cases of malignant tumors)and 12 cases of ovarian metastases from gastric cancer who underwent surgical treatment in Norinco General Hospital from March 2021 to March 2024 was performed.The difference in positive expression rates of CD24 and Smac in primary ovarian cancer and ovarian metastases from gastric cancer,and their relationships with clinical pathological parameters were compared.Spearman analysis was used to analyze the correlation of the expression of CD24 with Smac in ovarian cancer.ResultsThe positive expression rate of CD24 in malignant tumors(84.78%,39/46)was higher than that in borderline tumors(55.56%,10/18)and benign tumors(13.33%,2/15),P<0.05.The positive expression rate of Smac in benign tumors(86.67%,13/15)was higher than that in borderline tumors(66.67%,12/18)and malignant tumors(60.87%,28/46),P<0.05.In patients with primary ovarian cancer,the positive expression rate of CD24 in patients with omental metastasis was higher than that in patients without omental metastasis(χ^(2)=7.14,P<0.05),the positive expression rate of CD24 in stageⅢ-Ⅳtissues was higher than that in stageⅠ-Ⅱtissues(χ^(2)=6.26,P<0.05),the positive expression rate of CD24 in patients with lymph node metastasis was higher than that in patients without lymph node metastasis(χ^(2)=4.57,P<0.05).In patients with primary ovarian cancer,the positive expression rate of Smac in patients with lymph node metastasis was lower than that in patients without lymph node metastasis(χ^(2)=4.76,P<0.05),the positive expression of Smac in stageⅠ-Ⅱtissues was higher than that in stageⅢ-Ⅳtissues(χ^(2)=4.00,P<0.0

关 键 词：卵巢癌 细胞粘附分子24 第二线粒体源性半胱氨酸酶激活因子 胃癌转移卵巢癌 

分 类 号：R73[医药卫生—肿瘤]